Home > Oncology > Gemcitabine maintenance after first-line chemo prolongs PFS in malignant mesothelioma

Gemcitabine maintenance after first-line chemo prolongs PFS in malignant mesothelioma

Journal
Lancet Respiratory Medicine
Reuters Health - 05/02/2021 - Gemcitabine maintenance therapy after first-line chemotherapy significantly prolonged progression-free survival (PFS) in patients with malignant mesothelioma, according to results of the Dutch NVALT19 trial. "Almost all patients with malignant mesothelioma eventually have disease progression after first-line therapy. Previous studies have investigated maintenance therapy, but none has shown a great effect," Dr. Cornedine J. de Gooijer of the Netherlands Cancer Institute, in Amsterdam, and colleagues point out in The Lancet Respiratory Medicine. NVALT19 was a randomized, open-label, phase-2 trial conducted in 18 hospitals in the Netherlands. The trial enrolled 130 adults with unresectable malignant mesothelioma with no evidence of disease progression after at least four cycles of first-line chemotherapy with platinum and pemetrexed, WHO performance status of 0 to 2, adequate organ function and measurable or evaluable disease. Half...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on